Cognitive Stimulation for Individuals with Parkinson’s Disease Dementia Living in Long-Term Care: Preliminary Data from a Randomized Crossover Pilot Study
Table 1
Baseline sociodemographic and clinical characteristics of the study sample.
Group A ()
Group B ()
value
Age (years)
76.67 ± 5.58
76.50 ± 8.94
0.970
Gender (male/female)
5/1
5/1
1.000
Years of education
10.17 ± 1.60
9.50 ± 0.55
0.445
Family status
0.392
Unmarried
0
1
Married
3
1
Divorced
0
1
Widowed
3
3
Inpatient (months)
16.50 ± 14.95
10.33 ± 5.50
0.394
Hoehn & Yahr stage
0.255
1–1.5
0
0
2–2.5
2
1
3
0
2
4
2
2
5
2
1
Months since PD diagnosis
72.00 ± 37.18
74.00 ± 48.84
0.938
Months since dementia diagnosis
26.17 ± 28.20
27.67 ± 12.66
0.908
LEDD
290.17 ± 236.60
239.67 ± 228.06
0.714
CCI
3.50 ± 3.78
2.33 ± 1.03
0.937
Number of antidementiva
0.83 ± 0.98
1.00 ± 0.63
0.699
Number of antidepressiva
0.83 ± 1.17
0.42 ± 0.66
0.699
Number of other medications
11.11 ± 3.27
10.42 ± 2.33
0.699
MMSE (max. 30 points)
17.50 ± 5.75
18.17 ± 5.35
0.839
CERAD total score (max. 111 points)
39.17 ± 9.37
38.50 ± 13.78
0.924
GDS (max. 15 points)
6.00 ± 2.00
8.67 ± 4.46
0.394
Values are presented as the mean ± standard deviation or frequency. Abbreviations: LEDD, levodopa equivalent daily dose; CCI, Charlson Comorbidity Index; MMSE, Mini-Mental State Examination; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; GDS, Geriatric Depression Scale.
